Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer By Ogkologos - December 19, 2025 441 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an updated analysis of the EMBER-3 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Breast Cancer Survivor Says Mistletoe Injections Have Kept Her Cancer-Free For... December 9, 2019 Virtual Mind–Body Fitness Classes Show Unexpected Benefit in People with Cancer December 15, 2023 Study Says Gold Particles Injected into Tumors May Improve Cancer Patients’... June 29, 2021 FDA Granted Accelerated Approval to Belantamab Mafodotin-blmf for Multiple Myeloma August 14, 2020 Load more HOT NEWS Trastuzumab Deruxtecan Demonstrates Durable Responses in Patients with Previously Treated HER2-mutated... ‘Will cancer make me infertile?’ – That Cancer Conversation Mutation Screening Could Reveal Whether Hormone Treatment Will Work for Breast... Foodie Friday: Butternut Squash Macaroni Casserole
